AstraZeneca plc (LON:AZN) was downgraded by Liberum Capital from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Thursday, MarketBeat reports. They currently have a GBX 5,000 ($64.57) price target on the biopharmaceutical company’s stock, up from their previous price target of GBX 4,800 ($61.99). Liberum Capital’s target price would indicate a potential upside of 5.94% from the stock’s current price.

Several other brokerages have also weighed in on AZN. Morgan Stanley reissued an “overweight” rating and set a GBX 5,600 ($72.32) target price on shares of AstraZeneca plc in a research report on Friday, June 23rd. UBS AG set a GBX 4,550 ($58.76) price target on AstraZeneca plc and gave the stock a “neutral” rating in a research note on Thursday, August 31st. Deutsche Bank AG restated a “buy” rating on shares of AstraZeneca plc in a research note on Monday, May 22nd. Jefferies Group LLC raised their price target on AstraZeneca plc from GBX 4,350 ($56.18) to GBX 4,800 ($61.99) and gave the stock a “hold” rating in a research note on Monday, September 11th. Finally, Shore Capital restated a “hold” rating on shares of AstraZeneca plc in a research note on Tuesday, August 29th. Three investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and nine have given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of GBX 5,022.91 ($64.87).

AstraZeneca plc (LON AZN) traded down 1.80% during trading on Thursday, reaching GBX 4719.50. The company’s stock had a trading volume of 3,225,455 shares. AstraZeneca plc has a 1-year low of GBX 3,996.00 and a 1-year high of GBX 5,520.00. The stock has a 50 day moving average price of GBX 4,556.15 and a 200 day moving average price of GBX 4,880.61. The stock’s market capitalization is GBX 59.75 billion.

WARNING: This report was first reported by American Banking News and is owned by of American Banking News. If you are accessing this report on another website, it was stolen and republished in violation of United States & international trademark and copyright legislation. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/09/17/liberum-capital-downgrades-astrazeneca-plc-azn-to-hold.html.

In related news, insider Nazneen Rahman bought 39 shares of the firm’s stock in a transaction dated Thursday, July 27th. The stock was bought at an average price of GBX 4,370 ($56.44) per share, with a total value of £1,704.30 ($2,201.08).

About AstraZeneca plc

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.